SCHEMBL85523

SCHEMBL85523

CCOC(=O)Cc1ccc(N)cc1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPID Q08752 2/20 0.58
PPIB P23284 1/20 0.58
PPIA P62937 1/20 0.58
PPIG Q13427 1/20 0.58
LMNA P02545 4/20 0.56
CYP1A2 P05177 1/20 0.56
CYP3A4 P08684 1/20 0.56
MAOA P21397 1/20 0.56
CYP4Z1 Q86W10 1/20 0.54
MAPT P10636 2/20 0.51
ALDH1A1 P00352 3/20 0.49
SMN1; SMN2 Q16637 2/20 0.49
KDM4E B2RXH2 2/20 0.49
HTT P42858 1/20 0.49
PPARG P37231 1/20 0.48
CYP4F2 P78329 1/20 0.47
CYP4A11 Q02928 1/20 0.47
TSHR P16473 1/20 0.46
HSD17B10 Q99714 1/20 0.46
TBXAS1 P24557 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL77910 0.98 PPIB (0.56) PPIDPPIBPPIAPPIGLMNA
SCHEMBL68851 0.90 CYP4Z1 (0.62) LMNACYP4Z1MAPTALDH1A1SMN1; SMN2
SCHEMBL10461745 0.85 CYP4F2 (0.53) PPIDPPIBPPIAPPIGLMNA
SCHEMBL11038201 0.85 CYP1A2 (0.47) PPIDPPIBPPIAPPIGLMNA
SCHEMBL19346039 0.85 LMNA (0.48) PPIDPPIBPPIAPPIGLMNA
SCHEMBL480039 0.85 CYP4Z1 (0.54) LMNACYP1A2CYP4Z1MAPTALDH1A1
Hydrochloric Acid SCHEMBL27427984 0.84 LMNA (0.49) PPIDPPIBPPIAPPIGLMNA
SCHEMBL10299459 0.84 CYP4Z1 (0.57) LMNACYP4Z1MAPTALDH1A1SMN1; SMN2
SCHEMBL6057577 0.84 CYP4F2 (0.59) LMNACYP4Z1MAPTALDH1A1SMN1; SMN2
SCHEMBL1107146 0.84 CYP4Z1 (0.57) LMNACYP1A2CYP4Z1MAPTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1026 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119613279-A N-substituted benzene ring bioisostere and preparation method thereof 上海交通大学 2025-03-14 CN claimed
CN-118955358-A FXR partial agonist containing piperidine structure, and preparation method and application thereof 桂林医学院 2024-11-15 CN claimed
CN-114736159-B Photo-crosslinking molecular probe and preparation method and application thereof 南京医科大学 2024-05-07 CN claimed
CN-117551311-A Composite cable 顺磊线缆有限公司 2024-02-13 CN claimed
CN-117285504-A Amino phenylacetamide derivative and preparation method and application thereof 桂林医学院 2023-12-26 CN claimed
CN-114736159-A Photo-crosslinking molecular probe and preparation method and application thereof 南京医科大学 2022-07-12 CN claimed
JP-58194814-A None JP disclosed
US-20260083723-A1 THERAPEUTIC AGENT OR PROPHYLACTIC AGENT FOR AMYOTROPHIC LATERAL SCLEROSIS TORAY INDUSTRIES, INC. (JP) 2026-03-26 US disclosed
US-12570639-B2 Tetrahydroquinoline derivative and medicinal use thereof TORAY INDUSTRIES, INC. (JP) 2026-03-10 US disclosed
US-20260008788-A1 AZA-FUSED RING COMPOUND, PREPARATION METHOD THEREFOR, AND USE THEREOF IN MEDICINE SUZHOU ARK BIOPHARMACEUTICAL CO LTD (CN) 2026-01-08 US disclosed
EP-4673450-A1 TETRAHYDROQUINOLINE DERIVATIVES FOR INHIBITING CAV3.2-USP5 INTERACTIONS Zymedyne Therapeutics Inc. (CA) 2026-01-07 EP disclosed
EP-4674852-A1 PREPARATION METHOD FOR AND USE OF DIHYDROTHIENOPYRIMIDINE DERIVATIVE Innovstone Therapeutics Limited (CN) 2026-01-07 EP disclosed
CN-120921764-B Fireproof heat insulation plate and preparation method thereof 河北国美新型建材有限公司 2025-12-16 CN disclosed
US-4163788-A ANTIINFLAMMATORY CIBA-GEIGY CORPORATION (US) 1979-08-07 US disclosed
US-4138570-A METHINE DYE BAYER AKTIENGESELLSCHAFT (DE) 1979-02-06 US disclosed
US-4126691-A ANTIINFLAMMATORY CIBA-GEIGY CORPORATION (US) 1978-11-21 US disclosed
US-3997669-A ANTIINFLAMMATORY CIBA-GEIGY CORPORATION (US) 1976-12-14 US disclosed
US-3993763-A ALPHA-(CYCLIC TERTIARY AMINO-PHENYL)-ALIPHATIC ACIDS CIBA-GEIGY CORPORATION (US) 1976-11-23 US disclosed
US-3957850-A ANALGESICS, ANTIINFLAMMATORY AGENTS BOUCHARA EMILE 1976-05-18 US disclosed
US-3936467-A ANTIINFLAMMATORY CIBA-GEIGY CORPORATION (US) 1976-02-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260083723-A1 THERAPEUTIC AGENT OR PROPHYLACTIC AGENT FOR AMYOTROPHIC LATERAL SCLEROSIS AIFM2, GPX1, SOD1 PPID 3563/4885PPIB 2815/4885PPIA 3805/4885
US-20260008788-A1 AZA-FUSED RING COMPOUND, PREPARATION METHOD THEREFOR, AND USE THEREOF IN MEDICINE PDE4B, PDE4A, CYP4A11 PPID 1533/4885PPIB 2801/4885PPIA 3080/4885
US-12570639-B2 Tetrahydroquinoline derivative and medicinal use thereof AIFM2, GPX1, GPX4 PPID 3175/4885PPIB 2856/4885PPIA 3581/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.